- Threshold Pharmaceuticals' (THLD) TH-302 performed well in combination with antiangiogenic agents, which inhibit the growth of new blood vessels, in two Phase I studies.
- In one trial, TH-302 was used with GSK's (GSK) Votrient for treating advanced solid tumors, achieving a clinical benefit rate of 76% (partial response rate of 12% plus a stable disease rate of 64%).
- In another study, TH-302 brought partial responses when used with Pfizer's (PFE) Sutent in patients with renal cell carcinoma (kidney cancer) and gastrointestinal stromal tumors.
- All tumors eventually become resistant to antiangiogenics, says Dr Hebert Hurwitz of Duke Cancer Institute. "Co-targeting tumor angiogenesis and tumor hypoxia, which is believed to be a key driver of treatment resistance, is one approach to potentially prevent or reverse this mechanism of resistance."
- Threshold's shares are +9.7%. (PR)
Threshold rises follow Phase I results for cancer drug
Oct 21 2013, 07:40 ET